These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 29589679)

  • 21. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
    Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
    Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
    Parmar V; Hawaldar R; Nair NS; Shet T; Vanmali V; Desai S; Gupta S; Rangrajan V; Mittra I; Badwe RA
    Breast; 2013 Dec; 22(6):1081-6. PubMed ID: 23948301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
    Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
    Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower nodal counts in axillary dissection following neoadjuvant chemotherapy: are there implications?
    Callcut RA; Breslin TM
    Am J Surg; 2006 Jun; 191(6):830-1. PubMed ID: 16720160
    [No Abstract]   [Full Text] [Related]  

  • 26. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of ultrasound-guided biopsy of suspicious axillary lymph nodes in the selection of patients with extensive axillary tumour burden in breast cancer.
    van Wely BJ; de Wilt JH; Francissen C; Teerenstra S; Strobbe LJ
    Br J Surg; 2015 Feb; 102(3):159-68. PubMed ID: 25354962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
    Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
    Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axillary management after neoadjuvant treatment.
    Montagna G; Corso G; Di Micco R; Van Den Rul N; Rocco N
    Minerva Chir; 2020 Dec; 75(6):400-407. PubMed ID: 33345526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Aguayo-Albasini JL
    Cir Esp (Engl Ed); 2020 Nov; 98(9):510-515. PubMed ID: 32386728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sentinel node biopsy in conservative surgery for breast cancer: a changing role in clinical practice.
    Magnoni F; Veronesi P
    Minerva Chir; 2020 Dec; 75(6):386-391. PubMed ID: 32975389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
    Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
    Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Will we need lymph node dissection at all in the future?
    Bourez RL; Rutgers EJ; Van De Velde CJ
    Clin Breast Cancer; 2002 Dec; 3(5):315-22; discussion 323-5. PubMed ID: 12533260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
    J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience.
    Zhang GC; Liao N; Guo ZB; Qian XK; Ren CY; Yao M; Li XR; Wang K; Zu J
    Clin Transl Oncol; 2013 Jan; 15(1):79-84. PubMed ID: 22926944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study.
    Coufal O; Zapletal O; Gabrielová L; Fabian P; Schneiderová M
    Rozhl Chir; 2018; 97(12):551-557. PubMed ID: 30646734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
    Di Micco R; Zuber V; Fiacco E; Carriero F; Gattuso MI; Nazzaro L; Panizza P; Gianolli L; Canevari C; Di Muzio N; Pasetti M; Sassi I; Zambetti M; Gentilini OD
    Eur J Surg Oncol; 2019 Jun; 45(6):969-975. PubMed ID: 30744944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
    Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
    Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.